Why Fractured Catheter Fragments Must Be Removed
The standard of care for a retained intravascular catheter fragment is retrieval whenever technically feasible and procedurally safe for the patient. Reasons for retrieval include: prevention of bacterial colonization and biofilm formation that causes recurrent bloodstream infections; elimination of the arrhythmogenic (arrhythmia-causing) mechanical irritation of the right ventricular endocardium; prevention of cardiac perforation from fragment movement; removal of the thrombogenic foreign body that promotes clot formation; and elimination of the inflammatory stimulus that drives pulmonary vascular remodeling and pulmonary hypertension.
The decision to retrieve is individualized. A fragment clearly accessible in the right atrium or main pulmonary artery via percutaneous snare technique poses lower procedural risk and retrieval is strongly favored. A fragment deeply embedded in peripheral pulmonary arteries or already partially endothelialized (incorporated into vessel wall tissue) may pose higher retrieval risk than retention risk in elderly or medically fragile patients. Interventional cardiologists and cardiothoracic surgeons must weigh these considerations on a case-by-case basis. The fact that retrieval is required — whether percutaneous or surgical — is itself evidence of significant harm caused by the device defect.
Percutaneous Catheter-Based Retrieval
Percutaneous retrieval is performed by an interventional radiologist or interventional cardiologist in a cardiac catheterization laboratory using fluoroscopic guidance (live X-ray). A retrieval catheter is introduced via the femoral vein in the groin and advanced under fluoroscopic visualization to the fragment location. A snare device — a loop of wire — or a basket catheter is used to capture the fragment and pull it back through the venous system for removal through the femoral access sheath. The procedure typically requires conscious sedation and local anesthesia. Success rates for right-heart and main pulmonary artery fragments approach 70-90%, but peripheral pulmonary artery fragments are significantly more challenging and may require multiple attempts or specialized retrieval tools.
Open Surgical Retrieval
When percutaneous retrieval fails, is anatomically not feasible, or when the fragment has caused cardiac injury requiring direct surgical repair, open thoracic or cardiac surgery is required. The cardiothoracic surgeon performs a sternotomy (incision through the breastbone) or thoracotomy (incision between the ribs) under general anesthesia. In cases where the fragment is in the right ventricle or has perforated the cardiac wall, cardiopulmonary bypass (heart-lung machine support) may be required during the surgical repair. Recovery from open cardiac surgery involves ICU care, extended hospitalization (typically 5-10 days or more), and a prolonged recovery period of 4-8 weeks. Scarring, post-thoracotomy pain syndrome, and the psychological impact of major cardiac surgery are compensable damages in PowerPort litigation.
Documentation for Your Legal Claim
The retrieval procedure generates critical legal documentation: the interventional radiology or surgical operative report describing the fragment location, appearance, and retrieval method; the pathology report if the fragment was sent to pathology (which can confirm the polyurethane material and degradation features); and the procedural imaging (fluoroscopy, cine loops, or intraoperative photographs) showing the fragment in situ before retrieval. Patients and attorneys should ensure that all retrieval-related records are preserved, including the physical device fragment if it was retained by the hospital pathology department. This documentation is foundational to the causation evidence in a PowerPort lawsuit.
Frequently Asked Questions
Related Pages
PowerPort Catheter Fracture — How It Happens
Bard PowerPort catheters fracture through a well-documented mechanism called environmental stress cracking (ESC) of polyurethane — a process that was scientifically foreseeable at the time of device design. The fracture is silent and painless, meaning most patients have no idea their catheter has broken until complications force diagnostic imaging.
PowerPort MDL Settlement Timeline — What to Expect
MDL mass tort litigation follows a predictable multi-year progression from case filing through bellwether trials to global settlement. Understanding each phase helps PowerPort plaintiffs set realistic expectations for timing and the factors that determine individual settlement amounts.
PowerPort Catheter Migration — Where Fragments Go
When a PowerPort catheter fractures, the free fragment enters the central venous circulation and travels to the heart and lungs following the path of venous blood flow. The fragment's final resting location determines the severity of injury — from retrievable right-heart positions to life-threatening peripheral pulmonary artery lodgment.
Bard PowerPort MDL in the District of Arizona
MDL No. 3:22-md-03062 in the U.S. District Court for the District of Arizona is the central federal forum for all Bard PowerPort catheter fracture cases. Understanding how the MDL works, where it currently stands, and what participation means for individual plaintiffs is essential for anyone considering a PowerPort lawsuit.
PowerPort vs. Other Port Catheters — Key Differences
The Bard PowerPort's polyurethane catheter is the defining design characteristic that distinguishes it from safer alternatives like Hickman catheters, silicone Mediport devices, and PICC lines — none of which use polyurethane tubing and none of which carry the same environmental stress cracking fracture risk.
PowerPort Sepsis and Infection Risk
A fractured PowerPort catheter fragment acts as a permanent intravascular nidus for infection — a foreign body that bacteria colonize with a protective biofilm that antibiotics cannot eradicate without removing the fragment. For immunocompromised cancer patients, this infection risk is particularly life-threatening.
PowerPort Cardiac Perforation — Heart Surgery Risk
Cardiac perforation by a fractured PowerPort catheter fragment is a life-threatening emergency. The thin-walled right ventricle is particularly vulnerable to penetration by a fragment's sharp edge, causing cardiac tamponade — a surgical emergency that can be fatal within minutes without treatment.
Becton Dickinson Liability — BD's Acquisition of Bard
Becton, Dickinson and Company (BD) acquired C.R. Bard in 2017 for $24 billion and assumed full corporate liability for all Bard product claims, including the PowerPort. BD now faces claims not only for Bard's pre-acquisition conduct but also for BD's own post-acquisition decisions to continue selling the PowerPort without redesigning or adequately warning about the fracture risk.
PowerPort Evidence and Records — What You Need for Your Case
Building a strong PowerPort catheter lawsuit requires gathering specific categories of medical and device records. Even if you no longer have the physical device, documentary evidence of the fracture, fragment location, and resulting injury is sufficient to support a claim.
Bard PowerPort Catheter Lawsuit
The Bard PowerPort is an implantable venous access device — a small port placed under the skin, typically in the chest — that allows medical professionals to administer chemotherapy, draw blood, and deliver medications without repeated needle sticks. Millions of patients have received PowerPort devices since C.R. Bard introduced them in the 1990s. The devices are especially common among cancer patients who require long-term intravenous access. Beginning in the early 2010s, patients, physicians, and researchers began documenting a disturbing pattern: the polyurethane catheter tubing attached to the port was fracturing inside the body. Fragments of the catheter — sometimes several centimeters long — were entering the bloodstream and migrating toward the heart and lungs. The resulting complications range from serious to fatal: cardiac perforation, cardiac tamponade, pulmonary embolism, sepsis, and endocarditis. Becton Dickinson (BD) acquired C.R. Bard in 2017 for $24 billion, inheriting both the PowerPort product line and the mounting litigation. In 2022, a federal multidistrict litigation was established in the U.S. District Court for the District of Arizona to consolidate cases nationwide. Legal claims proceed under theories of design defect, manufacturing defect, failure to warn, and negligence. Patients who received a PowerPort catheter and subsequently experienced catheter fracture, fragment migration, infection, cardiac complications, or unexplained symptoms may be entitled to substantial compensation.
View full case overview